Special Issue "African Swine Fever Virus (ASFV): Immunity and Vaccine Development"
Deadline for manuscript submissions: 31 January 2024 | Viewed by 7194
African swine fever virus (ASFV) is a causative agent of highly contagious and acute viral hemorrhagic disease; African swine fever (ASF) in domestic swine and wild boars is associated with significantly high mortality. ASFV is the only member of the family Asfaviridae, genus Asfivirus. It is a large, enveloped, and double-stranded DNA (dsDNA) virus that contains a linear DNA genome of 170 to 190 kb with more than 150 open reading frames (ORFs). Unfortunately, since its first description in Kenya in 1921, no commercial vaccines or approved anti-ASFV drugs are currently available. Therefore, the virus is spreading in Africa, Europe, and Asia, especially in China, with devastating social–economic consequences for the development of the swine industry and domestic food security. The unavailability of an applicable ASF vaccine is partly due to the complex nature of the virus, which encodes several proteins associated with immune evasion. Moreover, the incomplete understanding of immune protection determinants of ASFV hampers rational vaccine design. However, scientists work tirelessly to develop promising ASF vaccines, especially live attenuated and DNA vaccines.
This Special Issue of Vaccines aims to contribute to the current knowledge regarding immune evasion mechanisms used by the virus to establish an infection and approaches to vaccine development that are likely to benefit hosts upon subsequent natural infection. Original research articles, review articles, as well as short communications are invited.
Dr. Kiramage Chathuranga
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- African Swine Fever virus
- immune evasion